Prevalence and undiagnosed fraction of hepatitis C infection in 2018 in Spain: results from a national population-based survey

Background: A national strategy against hepatitis C virus (HCV) was implemented in Spain in 2015 with the aim of reducing associated morbidity and mortality. In order to improve our understanding of the epidemiology of HCV, we analysed the prevalence of HCV antibodies and active infection overall an...

ver descrição completa

Detalhes bibliográficos
Autores: Estirado Gómez, Alicia, Justo Gil, Soledad, Limia, Aurora, Avellón, Ana, Arce Arnáez, Araceli, González-Rubio, Raquel, Diaz Franco, Asuncion, Del Amo, Julia, Working group of the HCV prevalence study in Spain in 2017-2018, De Ory, Fernando de, Masa-Calles, Josefa, Vazquez-Moreno, Julio Alberto, Abad, Raquel, Perez-Olmeda, Mayte, Fedele, Cesare Giovanni, Fernandez-Garcia, Aurora, Cabrerizo, Maria
Formato: artículo
Fecha de publicación:2021
País:España
Recursos:Instituto de Salud Carlos III (ISCIII)
Repositorio:Repisalud
Idioma:inglés
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/26239
Acesso em linha:https://hdl.handle.net/20.500.12105/26239
Access Level:acceso abierto
Palavra-chave:Antiviral Agents
Hepacivirus
Hepatitis C Antibodies
Hepatitis C
Humans
Male
Prevalence
Seroepidemiologic Studies
Spain
id ES_4da859ff8cb969b9e4d7f366ea3dbc29
oai_identifier_str oai:repisalud.isciii.es:20.500.12105/26239
network_acronym_str ES
network_name_str España
repository_id_str
spelling Prevalence and undiagnosed fraction of hepatitis C infection in 2018 in Spain: results from a national population-based surveyEstirado Gómez, AliciaJusto Gil, SoledadLimia, AuroraAvellón, AnaArce Arnáez, AraceliGonzález-Rubio, RaquelDiaz Franco, AsuncionDel Amo, JuliaWorking group of the HCV prevalence study in Spain in 2017-2018De Ory, Fernando deMasa-Calles, JosefaVazquez-Moreno, Julio AlbertoAbad, RaquelPerez-Olmeda, MayteFedele, Cesare GiovanniFernandez-Garcia, AuroraCabrerizo, MariaAntiviral AgentsHepacivirusHepatitis C AntibodiesHepatitis CHumansMalePrevalenceSeroepidemiologic StudiesSpainBackground: A national strategy against hepatitis C virus (HCV) was implemented in Spain in 2015 with the aim of reducing associated morbidity and mortality. In order to improve our understanding of the epidemiology of HCV, we analysed the prevalence of HCV antibodies and active infection overall and by age and sex in the general population aged 20-80 years. We also aimed to report the undiagnosed fraction. Methods: A national population-based seroprevalence survey was conducted in 2017-2018. A representative sample from the general population was selected using two-stage sampling. The prevalence of total HCV antibodies and of HCV RNA was calculated using inverse probability weighting based on bootstrapping. Results: Overall, we approached 17 496 persons; 9103 agreed to participate and met the eligibility criteria and 7675 were aged 20-80. We obtained a prevalence of HCV antibodies of 0.85% [95% confidence interval (CI): 0.64-1.08%] and of active infection of 0.22% (95% CI: 0.12-0.32%). The prevalence of active HCV infection was highest in men aged 50-59 (0.86%; 95% CI: 0.28-1.57%) and in men aged 60-69 years (0.72%; 95% CI: 0.27-1.28%). Prevalence was below 0.20% in the remaining age groups. The undiagnosed fraction for active HCV infection was 29.4%. Conclusion: This study shows that prevalence of HCV in the general population in Spain is low and reflects the impact of scaling up treatment with direct acting antivirals, together with other prevention strategies, from 2015 onwards. The data reported can guide subsequent public health actions.Oxford University PressMinisterio de Sanidad (España)20252025-02-0320212021-12-0120212021-12-01research articlehttp://purl.org/coar/resource_type/c_2df8fbb1VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articlehttps://hdl.handle.net/20.500.12105/26239reponame:Repisaludinstname:Instituto de Salud Carlos III (ISCIII)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:repisalud.isciii.es:20.500.12105/262392026-06-12T12:43:37Z
dc.title.none.fl_str_mv Prevalence and undiagnosed fraction of hepatitis C infection in 2018 in Spain: results from a national population-based survey
title Prevalence and undiagnosed fraction of hepatitis C infection in 2018 in Spain: results from a national population-based survey
spellingShingle Prevalence and undiagnosed fraction of hepatitis C infection in 2018 in Spain: results from a national population-based survey
Estirado Gómez, Alicia
Antiviral Agents
Hepacivirus
Hepatitis C Antibodies
Hepatitis C
Humans
Male
Prevalence
Seroepidemiologic Studies
Spain
title_short Prevalence and undiagnosed fraction of hepatitis C infection in 2018 in Spain: results from a national population-based survey
title_full Prevalence and undiagnosed fraction of hepatitis C infection in 2018 in Spain: results from a national population-based survey
title_fullStr Prevalence and undiagnosed fraction of hepatitis C infection in 2018 in Spain: results from a national population-based survey
title_full_unstemmed Prevalence and undiagnosed fraction of hepatitis C infection in 2018 in Spain: results from a national population-based survey
title_sort Prevalence and undiagnosed fraction of hepatitis C infection in 2018 in Spain: results from a national population-based survey
dc.creator.none.fl_str_mv Estirado Gómez, Alicia
Justo Gil, Soledad
Limia, Aurora
Avellón, Ana
Arce Arnáez, Araceli
González-Rubio, Raquel
Diaz Franco, Asuncion
Del Amo, Julia
Working group of the HCV prevalence study in Spain in 2017-2018
De Ory, Fernando de
Masa-Calles, Josefa
Vazquez-Moreno, Julio Alberto
Abad, Raquel
Perez-Olmeda, Mayte
Fedele, Cesare Giovanni
Fernandez-Garcia, Aurora
Cabrerizo, Maria
author Estirado Gómez, Alicia
author_facet Estirado Gómez, Alicia
Justo Gil, Soledad
Limia, Aurora
Avellón, Ana
Arce Arnáez, Araceli
González-Rubio, Raquel
Diaz Franco, Asuncion
Del Amo, Julia
Working group of the HCV prevalence study in Spain in 2017-2018
De Ory, Fernando de
Masa-Calles, Josefa
Vazquez-Moreno, Julio Alberto
Abad, Raquel
Perez-Olmeda, Mayte
Fedele, Cesare Giovanni
Fernandez-Garcia, Aurora
Cabrerizo, Maria
author_role author
author2 Justo Gil, Soledad
Limia, Aurora
Avellón, Ana
Arce Arnáez, Araceli
González-Rubio, Raquel
Diaz Franco, Asuncion
Del Amo, Julia
Working group of the HCV prevalence study in Spain in 2017-2018
De Ory, Fernando de
Masa-Calles, Josefa
Vazquez-Moreno, Julio Alberto
Abad, Raquel
Perez-Olmeda, Mayte
Fedele, Cesare Giovanni
Fernandez-Garcia, Aurora
Cabrerizo, Maria
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Ministerio de Sanidad (España)
dc.subject.none.fl_str_mv Antiviral Agents
Hepacivirus
Hepatitis C Antibodies
Hepatitis C
Humans
Male
Prevalence
Seroepidemiologic Studies
Spain
topic Antiviral Agents
Hepacivirus
Hepatitis C Antibodies
Hepatitis C
Humans
Male
Prevalence
Seroepidemiologic Studies
Spain
description Background: A national strategy against hepatitis C virus (HCV) was implemented in Spain in 2015 with the aim of reducing associated morbidity and mortality. In order to improve our understanding of the epidemiology of HCV, we analysed the prevalence of HCV antibodies and active infection overall and by age and sex in the general population aged 20-80 years. We also aimed to report the undiagnosed fraction. Methods: A national population-based seroprevalence survey was conducted in 2017-2018. A representative sample from the general population was selected using two-stage sampling. The prevalence of total HCV antibodies and of HCV RNA was calculated using inverse probability weighting based on bootstrapping. Results: Overall, we approached 17 496 persons; 9103 agreed to participate and met the eligibility criteria and 7675 were aged 20-80. We obtained a prevalence of HCV antibodies of 0.85% [95% confidence interval (CI): 0.64-1.08%] and of active infection of 0.22% (95% CI: 0.12-0.32%). The prevalence of active HCV infection was highest in men aged 50-59 (0.86%; 95% CI: 0.28-1.57%) and in men aged 60-69 years (0.72%; 95% CI: 0.27-1.28%). Prevalence was below 0.20% in the remaining age groups. The undiagnosed fraction for active HCV infection was 29.4%. Conclusion: This study shows that prevalence of HCV in the general population in Spain is low and reflects the impact of scaling up treatment with direct acting antivirals, together with other prevention strategies, from 2015 onwards. The data reported can guide subsequent public health actions.
publishDate 2021
dc.date.none.fl_str_mv 2021
2021-12-01
2021
2021-12-01
2025
2025-02-03
dc.type.none.fl_str_mv research article
http://purl.org/coar/resource_type/c_2df8fbb1
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/20.500.12105/26239
url https://hdl.handle.net/20.500.12105/26239
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Oxford University Press
publisher.none.fl_str_mv Oxford University Press
dc.source.none.fl_str_mv reponame:Repisalud
instname:Instituto de Salud Carlos III (ISCIII)
instname_str Instituto de Salud Carlos III (ISCIII)
reponame_str Repisalud
collection Repisalud
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869407705997770752
score 15,812455

Registos relacionados